drugset / Trial / NCT06787183

SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases

NCT06787183

Phase 2 Recruiting 42 enrolled Fujian Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

To enhance the treatment efficacy of rectal cancer liver metastasis through a multidisciplinary approach of radiotherapy, immunotherapy, and chemotherapy, and to provide a new direction for the combination treatment strategy.

Timeline

Start
2025-12-01
Primary completion
2026-12-01
Completion
2029-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1000 mg/m2
Subject Oxaliplatin Small molecule 130 mg/m2
Subject QL1706 Monoclonal antibody 5 mg/kg

Indications